The role of CCAAT enhancer‐binding protein homologous protein in human immunodeficiency virus protease‐inhibitor–induced hepatic lipotoxicity in mice
Yun Wang, Luyong Zhang, Xudong Wu, Emily C. Gurley, Elaine Kennedy, Phillip B. Hylemon, William M. Pandak, Arun J. Sanyal, Huiping Zhou – 18 October 2012 – Human immunodeficiency virus (HIV) protease inhibitors (HIV PIs) are the core components of highly active antiretroviral therapy, which has been successfully used in the treatment of HIV‐1 infection in the past two decades. However, benefits of HIV PIs are compromised by clinically important adverse effects, such as dyslipidemia, insulin resistance, and cardiovascular complications.